Another partnership - Haematological Malignancies
https://xencor.com/pipeline/
Xencor - current market cap USD $2.072B
https://www.businesswire.com/news/h...reatment-of-Patients-With-B-Cell-Malignancies
Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies
-- Second agreement with Janssen on bispecific antibodies directed toward the CD28 co-stimulatory receptor on T cells --
Xencor to receive $100 million upfront payment and $25 million equity investment and is eligible for a mid-teen to low-twenties percent royalty for plamotamab and potential milestone payments up to $1.188 billion
- Forums
- ASX - By Stock
- RAC
- Industry news
Industry news, page-164
-
- There are more pages in this discussion • 1,956 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.65 |
Change
0.000(0.00%) |
Mkt cap ! $281.1M |
Open | High | Low | Value | Volume |
$1.65 | $1.66 | $1.65 | $51.86K | 31.42K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 17732 | $1.63 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.65 | 1867 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 17732 | 1.630 |
1 | 708 | 1.615 |
1 | 708 | 1.590 |
1 | 2000 | 1.570 |
1 | 1279 | 1.555 |
Price($) | Vol. | No. |
---|---|---|
1.650 | 1057 | 1 |
1.655 | 612 | 1 |
1.660 | 300 | 1 |
1.665 | 60 | 1 |
1.670 | 571 | 1 |
Last trade - 11.57am 29/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online